| Tarsus Pharmaceuticals (TARS) Loses -15.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner |
The heavy selling pressure might have exhausted for Tarsus Pharmaceuticals (TARS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
zacks.com |
2025-05-14 14:45:48 |
Czytaj oryginał (ang.) |
| Tarsus Pharmaceuticals: The "Get Big Fast" Approach Could Pay Off |
TARS has been marketing Xdemvy (lotilaner) aggressively, with Q1'25 seeing advertisement on network TV, moving beyond previous advertising on streaming platforms. TARS can expand lotilaner beyond Demodex blepharitis, with trials set to initiate in H2'25 in ocular rosacea and 2026 for Lyme disease prevention. TARS is guiding for up to a 25% increase in bottles of Xdemvy dispensed in Q2'25, compared to Q1'25, although the company has often beaten its guidance for bottles dispensed. |
seekingalpha.com |
2025-05-12 16:28:56 |
Czytaj oryginał (ang.) |
| Tarsus to Participate in Upcoming Investor Conferences |
IRVINE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that management plans to participate in the following upcoming investor conferences: |
globenewswire.com |
2025-05-08 21:00:00 |
Czytaj oryginał (ang.) |
| Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown |
GREENFIELD, Ind. , May 5, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the sale of certain future tiered royalties and commercial milestones associated with XDEMVY® (lotilaner ophthalmic solution) 0.25%, for the human health application of lotilaner, to funds affiliated with Blackstone Life Sciences and Blackstone Credit & Insurance for $295 million in cash. |
prnewswire.com |
2025-05-05 10:27:00 |
Czytaj oryginał (ang.) |
| Tarsus Pharmaceuticals, Inc. (TARS) Q1 2025 Earnings Call Transcript |
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants David Nakasone – Head-Investor Relations Bobby Azamian – Chief Executive Officer and Chairman Aziz Mottiwala – Chief Commercial Officer Jeff Farrow – Chief Financial Officer and Chief Strategy Officer Sesha Neervannan – Chief Operating Officer Conference Call Participants Lachlan Hanbury-Brown – William Blair Andrea Newkirk – Goldman Sachs Pavan Patel – Bank of America Eddie Hickman – Guggenheim Cory Jubinville – LifeSci Capital Operator Good day, ladies and gentlemen, and thank you for standing by. Welcome to Tarsus First Quarter 2025 Earnings Conference Call. |
seekingalpha.com |
2025-05-02 01:37:17 |
Czytaj oryginał (ang.) |
| Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates |
Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $1.01 per share a year ago. |
zacks.com |
2025-05-01 22:40:41 |
Czytaj oryginał (ang.) |
| Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements |
Generated $78.3 million in net product sales of XDEMVY ® , an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients |
globenewswire.com |
2025-05-01 20:05:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts See a 31.89% Upside in Tarsus Pharmaceuticals (TARS): Can the Stock Really Move This High? |
The mean of analysts' price targets for Tarsus Pharmaceuticals (TARS) points to a 31.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2025-04-30 14:55:36 |
Czytaj oryginał (ang.) |
| Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 |
IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, May 1, 2025, to report its first quarter 2025 financial results and provide a corporate update. |
globenewswire.com |
2025-04-24 21:00:00 |
Czytaj oryginał (ang.) |
| Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting |
IRVINE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) will present four distinct data sets highlighting the global prevalence and real-world patient burden of Demodex blepharitis, as well as the impact of XDEMVY® (lotilaner ophthalmic solution) 0.25% in addressing objective measures of disease at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting, taking place April 25-28, 2025, in Los Angeles, Calif. |
globenewswire.com |
2025-04-22 12:31:00 |
Czytaj oryginał (ang.) |
| Tarsus Announces Pricing of Upsized $125.0 Million Public Offering |
IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the pricing of an upsized underwritten public offering of 2,808,988 shares of its common stock at a public offering price of $44.50 per share. In addition, Tarsus has granted the underwriters a 30-day option to purchase up to an additional 421,348 shares of its common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Tarsus, are expected to be approximately $125.0 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on March 14, 2025, subject to the satisfaction of customary closing conditions. |
globenewswire.com |
2025-03-12 23:49:00 |
Czytaj oryginał (ang.) |
| Tarsus Announces Proposed $100.0 Million Public Offering |
IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the commencement of an underwritten public offering of $100.0 million of shares of its common stock. Tarsus also intends to grant the underwriters a 30-day option to purchase up to an additional $15.0 million of shares of its common stock offered in the proposed offering. All shares in the proposed offering are to be sold by Tarsus. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. |
globenewswire.com |
2025-03-12 18:12:00 |
Czytaj oryginał (ang.) |
| Tarsus Pharma: Strong Execution In Xdemvy Commercialization |
Tarsus Pharmaceuticals' Xdemvy, the first approved treatment for Demodex blepharitis, generated $180M in 2024 sales, with significant growth potential in a large addressable market. Analysts project Tarsus' revenue to reach $352M in 2025, driven by expanding sales, Medicare/Medicaid reimbursement, and increasing consumer awareness. Tarsus' pipeline includes promising candidates TP-04 for Ocular Rosacea and TP-05 for Lyme disease, enhancing long-term growth prospects. |
seekingalpha.com |
2025-03-11 14:36:17 |
Czytaj oryginał (ang.) |
| Tarsus to Participate in Upcoming Investor Conference |
IRVINE, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in a fireside chat at the Barclays 27th Annual Global Healthcare Conference on Tuesday, March 11th, at 8:00 a.m. / 11:00 a.m. ET. |
globenewswire.com |
2025-03-06 19:00:00 |
Czytaj oryginał (ang.) |
| Tarsus Pharmaceuticals, Inc. (TARS) Q4 2024 Earnings Call Transcript |
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q4 2024 Earnings Conference Call February 25, 2025 8:00 AM ET Company Participants David Nakasone - Head of IR Bobby Azamian - CEO and Chairman Aziz Mottiwala - CCO Seshadri Neervannan - COO Jeff Farrow - CFO and CSO Conference Call Participants Francois Brisebois - Oppenheimer Corey Jubinville - Life Sci Capital Jason Gerberry - Bank of America Oren Livnat - HC Wainright Eddie Hickman - Guggenheim Securities Andrea Newkirk - Goldman Sachs Lachlan Hanbury-Brown - William Blair Operator Good morning, and welcome to Tarsus Year End 2024 Financial Results Conference Call. As a reminder, this call is being recorded. |
seekingalpha.com |
2025-02-25 20:01:18 |
Czytaj oryginał (ang.) |
| Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Tops Revenue Estimates |
Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $1.31 per share a year ago. |
zacks.com |
2025-02-25 11:40:30 |
Czytaj oryginał (ang.) |
| Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025 |
IRVINE, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 5:00 a.m. PT / 8:00 a.m. ET on Tuesday, February 25, 2025, to report its fourth quarter and full-year 2024 financial results and provide a corporate update. |
globenewswire.com |
2025-02-20 19:00:00 |
Czytaj oryginał (ang.) |
| Tarsus to Participate in Upcoming Investor Conferences |
IRVINE, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in fireside chats at two upcoming investor conferences: |
globenewswire.com |
2025-01-30 19:00:00 |
Czytaj oryginał (ang.) |
| Down -9.11% in 4 Weeks, Here's Why Tarsus Pharmaceuticals (TARS) Looks Ripe for a Turnaround |
The heavy selling pressure might have exhausted for Tarsus Pharmaceuticals (TARS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
zacks.com |
2025-01-14 12:36:16 |
Czytaj oryginał (ang.) |
| Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care |
Advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, another large, underserved eye disease with no FDA-approved therapy; Initiation of Phase 2 study planned for 2H 2025 |
globenewswire.com |
2025-01-13 10:30:00 |
Czytaj oryginał (ang.) |
| 4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow |
Here, we discuss four biotech stocks, ADMA, TARS, STOK and CDXC, which have returned more than 50% year to date and have room for more growth in 2025. |
zacks.com |
2024-12-24 14:51:19 |
Czytaj oryginał (ang.) |
| Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks |
Jonathan Faison runs the ROTY Biotech Community. Why he's high on Tarsus Pharmaceuticals and his #1 holding, SpringWorks Therapeutics. |
seekingalpha.com |
2024-12-15 16:00:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think Tarsus Pharmaceuticals (TARS) Could Surge 26.98%: Read This Before Placing a Bet |
The consensus price target hints at a 27% upside potential for Tarsus Pharmaceuticals (TARS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2024-12-04 12:56:14 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Believe Tarsus Pharmaceuticals (TARS) Could Rally 41.09%: Here's is How to Trade |
The average of price targets set by Wall Street analysts indicates a potential upside of 41.1% in Tarsus Pharmaceuticals (TARS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-11-18 13:00:36 |
Czytaj oryginał (ang.) |
| Tarsus Pharmaceuticals, Inc. (TARS) Q3 2024 Earnings Call Transcript |
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants David Nakasone - Head, IR Bobby Azamian - Chairman & CEO Aziz Mottiwala - Chief Commercial Officer Jeff Farrow - CFO and CSO Sesha Neervannan - COO Elizabeth Yeu - Chief Medical Officer Conference Call Participants Eddie Hickman - Guggenheim Securities Lachlan Hanbury-Brown - William Blair Andrea Newkirk - Goldman Sachs Oren Livnat - HC Wainwright Balaji Prasad - Barclays Jason Gerberry - Bank of America Merrill Lynch Corey Jubinville - Life Sci Capital Francois Brisebois - Oppenheimer Operator Welcome to Tarsus' Third Quarter 2024 Financial Results Conference Call. As a reminder, this call is being recorded at this time, I would like to turn the call over to David Nakasone, Head of Investor Relations, to lead off the call. |
seekingalpha.com |
2024-11-14 00:23:06 |
Czytaj oryginał (ang.) |
| Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates |
Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $1.28 per share a year ago. |
zacks.com |
2024-11-13 20:31:12 |
Czytaj oryginał (ang.) |
| Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors |
Humana CMO brings more than two decades of experience driving innovative, value-based initiatives designed to improve patient outcomes |
globenewswire.com |
2024-11-13 10:30:00 |
Czytaj oryginał (ang.) |
| Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? |
Tarsus Pharmaceuticals (TARS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-11-07 13:00:30 |
Czytaj oryginał (ang.) |
| Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024 |
IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, November 13, 2024 to report its third quarter 2024 financial results and provide a corporate update. |
globenewswire.com |
2024-11-06 18:30:00 |
Czytaj oryginał (ang.) |
| Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer |
Dr. Yeu transitions from her role as Chief Medical Advisor and Board Member to lead the Company's newly created Medical Organization Dr. Yeu transitions from her role as Chief Medical Advisor and Board Member to lead the Company's newly created Medical Organization |
globenewswire.com |
2024-11-05 10:30:00 |
Czytaj oryginał (ang.) |
| Tarsus Pharmaceuticals (TARS) Surges 10.6%: Is This an Indication of Further Gains? |
Tarsus Pharmaceuticals (TARS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2024-10-30 09:41:10 |
Czytaj oryginał (ang.) |
| Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% |
Campaign showcases root cause of Demodex blepharitis through creative representation of mischief-causing mites on patients' eyelids |
globenewswire.com |
2024-10-17 12:30:00 |
Czytaj oryginał (ang.) |
| Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024 |
IRVINE, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Aziz Mottiwala, Chief Commercial Officer, will participate in a virtual fireside chat at the UBS Virtual Ophthalmology Day 2024 taking place on Wednesday, October 2, at 6:00 a.m. PT / 9:00 a.m. ET. |
globenewswire.com |
2024-09-25 21:00:00 |
Czytaj oryginał (ang.) |
| Tarsus Pharmaceuticals: Unlocking Growth Potential With Eye Care Innovations |
Tarsus Pharmaceuticals, Inc.'s Xdemvy, the first FDA-approved treatment for demodex blepharitis, has shown significant efficacy and rapid revenue growth, with $40.8M revenue in Q2 2024. The company is expanding its pipeline to target meibomian gland disease and rosacea, with promising Phase 2 results and ongoing FDA discussions. Strong financials with $323M in cash reserves, a healthy current ratio, and a projected positive cash flow by Q3 2024 support robust growth. |
seekingalpha.com |
2024-09-20 19:17:34 |
Czytaj oryginał (ang.) |
| Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference |
IRVINE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobby Azamian, M.D., Ph.D., Chief Executive Officer and Chairman, and Jeff Farrow, Chief Financial and Chief Strategy Officer, will participate in an in-person fireside chat at the 2024 Wells Fargo Securities Healthcare Conference taking place in Boston, MA, on Wednesday, September 4, at 11:15 a.m. PT / 2:15 p.m. ET. |
globenewswire.com |
2024-08-28 21:00:00 |
Czytaj oryginał (ang.) |
| Tarsus Pharmaceuticals: Strong Execution In Eye Disease Treatment |
Tarsus Pharma has a drug for Demodex blepharitis and multiple late-stage assets in its pipeline, including lotilaner for various formulations. The company has seen a 65% increase in stock value, with a $1 billion market opportunity in the initial addressable segment alone. TARS has promising data in trials for various conditions, including Lyme disease and Meibomian gland disease, with potential preventive and therapeutic benefits. |
seekingalpha.com |
2024-08-20 20:56:17 |
Czytaj oryginał (ang.) |
| Tarsus Pharmaceuticals, Inc. (TARS) Q2 2024 Earnings Call Transcript |
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants David Nakasone - Head, Investor Relations Bobby Azamian - Chairman and CEO Aziz Mottiwala - Chief Commercial Officer Jeff Farrow - Chief Financial Officer and CSO Sesha Neervannan - Chief Operating Officer Conference Call Participants Tim Lugo - William Blair Pavan Patel - BofA Dennis Kennedy - LifeSci Capital Talani Usman - Goldman Sachs Frank Brisebois - Oppenheimer Michaela Diverio - Barclays Eddie Hickman - Guggenheim Securities Operator Good afternoon. And welcome to the Tarsus' Second Quarter 2024 Financial Results Conference Call. |
seekingalpha.com |
2024-08-10 17:50:04 |
Czytaj oryginał (ang.) |
| Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates |
Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to loss of $1.17 per share a year ago. |
zacks.com |
2024-08-08 23:07:04 |
Czytaj oryginał (ang.) |
| Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024 |
IRVINE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, August 8, 2024 to report its second quarter 2024 financial results and provide a corporate update. |
globenewswire.com |
2024-07-29 20:30:00 |
Czytaj oryginał (ang.) |
| Tarsus to Participate in Upcoming Investor Conferences |
IRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that management will participate in the following conferences: |
globenewswire.com |
2024-05-29 21:00:00 |
Czytaj oryginał (ang.) |